Shilpa Medicare gets final approval for OERIS in India
Shilpa Medicare received final approval from India’s Subject Expert Committee under CDSCO to market OERIS, its extended-release ondansetron injection.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.